Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIUTENSEN-R vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DIUTENSEN-R is a combination of reserpine and chlorothiazide. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter (VMAT), leading to reduced sympathetic tone. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting natriuresis and reducing plasma volume.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension (FDA-approved indication for the combination product)
Hypertension
One tablet orally once daily. Each tablet contains 2.5 mg reserpine and 25 mg chlorthalidone.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal half-life: cryptenamine 9-10 h, methylothiazide 18-24 h, reserpine 50-100 h (prolonged due to enterohepatic recirculation and tissue binding; accumulation occurs with daily dosing)
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Reserpine is extensively metabolized in the liver via CYP450 enzymes; chlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: 59% (cryptenamine), 50% (methylothiazide), 7% (reserpine); Biliary/fecal: 21% (cryptenamine), 48% (methylothiazide), 90% (reserpine)
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Methylothiazide: 65-70% bound to albumin; Reserpine: 95% bound to alpha-1-acid glycoprotein and albumin; Cryptenamine: insufficient data
~90%, primarily to albumin
Methylothiazide: 0.25-0.3 L/kg (primarily extracellular fluid); Reserpine: 2.5-7 L/kg (extensive tissue binding, especially adipose and brain); Cryptenamine: ~1 L/kg (moderate distribution)
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: methylothiazide 90-100%; reserpine 50-60% (first-pass metabolism); cryptenamine 40-60% (variable first-pass)
Oral: 50–60% (extensive first-pass metabolism)
e GFR 30-50 m L/min: reduce dose by 50%; e GFR <30 m L/min: contraindicated.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh class A: no adjustment; class B or C: contraindicated.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended for use in children.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate therapy at half the standard adult dose (one-half tablet daily) and titrate cautiously due to increased sensitivity to adverse effects.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
Reserpine component: Risk of mental depression, which may be severe and can lead to suicide. Use with caution in patients with history of depression.
None
Monitor for signs of depression; discontinue if depression occurs.,Electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia) with chlorothiazide.,Orthostatic hypotension with reserpine.,Use cautiously in patients with peptic ulcer disease, renal impairment, or hepatic impairment.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Active peptic ulcer,Ulcerative colitis,History of mental depression,Electroshock therapy,Anuria,Hypersensitivity to reserpine, chlorothiazide, or sulfonamide-derived drugs
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-sodium foods to enhance antihypertensive effect. Grapefruit juice may increase hydralazine absorption; limit intake. Alcohol can exacerbate orthostatic hypotension. Maintain adequate potassium intake (bananas, oranges) unless otherwise instructed.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Use of reserpine component may be associated with increased risk of congenital malformations, but data are limited. Second and third trimesters: Reserpine can cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion; hydrochlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia, electrolyte imbalances, and volume depletion. Overall, this combination is classified as pregnancy category C (reserpine) and B (hydrochlorothiazide); avoid use in pregnancy unless benefit outweighs risk.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Reserpine is excreted into breast milk and may cause adverse effects in nursing infants (e.g., nasal congestion, respiratory depression, bradycardia). Hydrochlorothiazide is excreted in small amounts; M/P ratio is approximately 0.6. However, thiazides may suppress lactation. Safety not established; use during breastfeeding is not recommended.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Pregnancy may alter pharmacokinetics of both components; volume expansion may reduce hydrochlorothiazide efficacy. Dose adjustments should be individualized based on blood pressure response and electrolyte monitoring. Generally, use lowest effective dose; avoid in severe hypertension or preeclampsia where oral therapy is inadequate.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
DIUTENSEN-R is a fixed-dose combination of reserpine, hydralazine, and hydrochlorothiazide. Monitor for orthostatic hypotension, especially at initiation. Reserpine may cause nasal congestion and depression; avoid in patients with history of depression. Hydralazine can induce lupus-like syndrome; obtain ANA titers if symptoms develop. Hydrochlorothiazide may cause electrolyte disturbances; check serum potassium and magnesium periodically.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not stop abruptly.,Rise slowly from sitting or lying to prevent dizziness.,Report any signs of depression, unusual bruising, or joint pain.,Avoid excessive sunlight; use sunscreen.,Do not take over-the-counter cold medications without consulting your doctor.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIUTENSEN-R vs ALDORIL 15, answered by our medical review team.
DIUTENSEN-R is a Antihypertensive Combination that works by DIUTENSEN-R is a combination of reserpine and chlorothiazide. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter (VMAT), leading to reduced sympathetic tone. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting natriuresis and reducing plasma volume.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIUTENSEN-R and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIUTENSEN-R is: One tablet orally once daily. Each tablet contains 2.5 mg reserpine and 25 mg chlorthalidone.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIUTENSEN-R and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIUTENSEN-R is classified as Category C. First trimester: Use of reserpine component may be associated with increased risk of congenital malformations, but data are limited. Second and third trimesters: Reserpine can caus. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.